The FDA has granted Orphan Drug designation to TransCon hGH (lonapegsomatropin; Ascendis Pharma), a long-acting prodrug of somatropin, for the treatment for growth hormone deficiency.
The age at and cause of period cessation were not found to be associated with conventional cardiovascular risk factors across middle age and later life.
Jatenzo® (testosterone undecanoate; Clarus Therapeutics), an oral testosterone replacement therapy, is now available for the treatment of hypogonadism.
The American College of Physicians has issued a set of recommendations to clarify the potential benefits and harms of testosterone therapy in men with age-related low testosterone.
For postmenopausal women, conjugated equine estrogen alone is associated with a long-term decrease in breast cancer incidence, while CEE plus medroxyprogesterone acetate is associated with increased incidence.
Older men receiving testosterone treatment with higher waist-to-hip ratio experience greater increases in noncalcified coronary plaque volume.
Testosterone replacement therapy may improve body composition in young male cancer survivors with borderline-low testosterone levels.
For men with and without hypogonadism, testosterone therapy is associated with an increased short-term risk for venous thromboembolism.
Longer use of estrogen hormone therapy is associated with higher cognitive status in late life.
In patients with overweight or obesity who undergo total thyroidectomy, choosing the thyroid hormone replacement dose based on body weight is frequently inaccurate and could be responsible for prolongation of the titration period.
